Description
Depo-Medrol Injection for Dogs and Horses is used to alleviate pain and lameness associated with osteoarthritis and arthritic conditions in dogs and horses. Depo Medrol for dogs is also beneficial in relieving allergic dermatitis and other allergy related skin conditions in dogs and cats. Each ml of Depo-Medrol contains 20 mg/ml methylprednisolone acetate.
Depo Medrol for dogs
Depo-Medrol is given by intramuscular injection. The average dosage for dogs is 20 mg IM, with a range of 2 mg – 40 mg in accordance with the size of dog and severity of condition. The average dosage for cats is 10 mg, with a range up to 20 mg. The usual dosage for horses is 200 mg IM, repeated as necessary. Following intramuscular injection of methylprednisolone acetate, a prolonged systemic effect results. Methylprednisolone acetate.
Depo Medrol for dogs Description
Depo Medrol for dogs is a synthetic corticosteroid used in the treatment of many different conditions, including autoimmune diseases such as lupus and some hemolytic anemias. It is also used to treat asthma and certain skin diseases in cats.
Animals Treated
Dogs, Cats & Horses
Depo Medrol Benefits
- Depo-Medrol is a powerful anti-inflammatory medication in injectable form
- Used to treat diseases associated with inflammation including certain allergies, skin conditions, and types of arthritis
- Can also be used to suppress the immune system
- It is quick-acting and has a longer period of activity than prednisone or prednisolone
Depo Medrol Dosage
Depo-Medrol has an effect on virtually every organ system in the body. Depo-Medrol is a corticosteroid that blocks the production of substances that trigger allergic and inflammatory actions. Depo-Medrol is used to modify the body’s immune response. At lower doses it helps to reduce inflammation by decreasing the activity of certain cells and chemicals produced by the body that cause inflammation. At higher doses, it can suppress the immune system by decreasing the number of cells necessary for a proper immune response.
Medrol for dogs
Active Ingredients
Methylprednisolone acetate sterile aqueous suspension
Dosage
20 mg/mL
Directions
Intramuscular
Following intramuscular injection of methylprednisolone acetate, a prolonged systemic effect results. The dose varies with the size of the animal patient, the severity of the condition under treatment, and the animal’s response to therapy.
Depo Medrol for horses
Horses.
The usual intramuscular dose for horses is 200 mg repeated as necessary.
For maintenance therapy in chronic conditions, initial doses should be reduced gradually until the smallest effective (ie, individualized) dose is established. MEDROL® Tablets containing methylprednisolone may also be used for maintenance in dogs and cats, administered according to the recommended dose.
When treatment is to be withdrawn after prolonged and intensive therapy, the dose should be reduced gradually.
If signs of stress are associated with the condition being treated, the dose should be increased. If a rapid hormonal effect of maximum intensity is required, as in anaphylactic shock, the intravenous administration of highly soluble SOLU-DELTA-CORTEF® Sterile Powder containing prednisolone sodium succinate is indicated.
DEPO Medrol for horses
Intrasynovial
Methylprednisolone acetate, a slightly soluble ester of methylprednisolone, is capable of producing a more prolonged local anti-inflammatory effect than equimolar doses of hydrocortisone acetate. Following intrasynovial injection, relief from pain may be experienced within 12 to 24 hours. The duration of relief varies, but averages three to four weeks, with a range of one to five or more weeks. Injections of methylprednisolone acetate have been well tolerated. Intrasynovial (intra-articular) injections may occasionally result in an increased localized inflammatory response.
Intrasynovial injection is recommended as an adjuvant to general therapeutic measures to effect suppression of inflammation in one or a few peripheral structures when (1) the disease is limited to one or a few peripheral structures; (2) the disease is widespread with one or a few peripheral structures actively inflamed; (3) systemic therapy with other corticoids or corticotropin controls all but a few of the more actively involved structures; (4) systemic therapy with cortisone, hydrocortisone, or corticotropin is contraindicated; (5) joints show early but actively progressing deformity (to enhance the effect of physiotherapy and corrective procedures); and (6) surgical or other orthopedic corrective measures are to be or have been done.
The action of DEPO-MEDROL Sterile Aqueous Suspension injected intrasynovially appears to be well localized since significant metabolic effects characteristic of systemic administration of adrenal steroids have not been observed. In a few instances mild and transient improvement of structures other than those injected have been reported. No other systemic effects have been noted. However, it is possible that mild systemic effects may occur following intrasynovial administration, and this possibility is greater the larger the number of structures injected and the higher the total dose employed.
